Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026)
Belite Bio (BLTE) posted quarterly Income from Continuing Operations of 26938000.0 for Q1 2026, down 88.68% year-over-year from 237991228.96 in Q1 2025, and up 99.89% on a QoQ basis from 25324000000.0 in Q4 2025.
Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Belite Bio (BLTE) has reported Income from Continuing Operations for 5 consecutive years, with 26938000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 88.68% year-over-year to 26938000.0; the TTM figure through Mar 2026 stood at 63360938000.0 (down 124.04% YoY), while the FY2025 annual figure was 75038000.0, down 107.61% from the prior year.
- Income from Continuing Operations came in at 26938000.0 for Q1 2026 at Belite Bio, up from 25324000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 6783000.0 in Q4 2022, with the low at 25324000000.0 in Q4 2025.
- Average Income from Continuing Operations over 5 years is 7377433062.5, with a median of 6853500000.0 recorded in 2023.
- Across the five-year window, Income from Continuing Operations sank 144392.13% in 2024 and jumped 99.82% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 6783000.0 in 2022, then decreased by 3.05% to 6990000.0 in 2023, then tumbled by 144392.13% to 10100000000.0 in 2024, then slumped by 150.73% to 25324000000.0 in 2025, then jumped by 99.89% to 26938000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 26938000.0, 25324000000.0, and 21690000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 74.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 378.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -453.82 Mn |
| 10 | Belite Bio | 96.77 Mn | 96.77 Mn | - | -26.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -25.32 Bn |
| Sep 30, 2025 | -21.69 Bn |
| Jun 30, 2025 | -16.32 Bn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -10.10 Bn |
| Sep 30, 2024 | -8.67 Bn |
| Jun 30, 2024 | -9.49 Bn |
| Mar 31, 2024 | -7.87 Bn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -6.81 Bn |
| Mar 31, 2023 | -6.90 Bn |
| Dec 31, 2022 | -6.78 Mn |
| Sep 30, 2022 | -2.40 Bn |
| Jun 30, 2022 | -2.39 Bn |